Dextall | $15,000,000 | (Jul 15, 2025)
Duranta | $7,000,000 | (Jul 15, 2025)
Circuit(US) | $4,500,000 | (Jul 15, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
ScienceMachine | $3,500,000 | (Jul 15, 2025)
Bastazo | $5,300,000 | (Jul 15, 2025)
Helios | $4,000,000 | (Jul 15, 2025)
GenPhoenix | $15,000,000 | (Jul 15, 2025)
Asepha | $4,000,000 | (Jul 15, 2025)
Moonvalley | $84,000,000 | (Jul 15, 2025)
MOTOR Ai | $20,000,000 | (Jul 15, 2025)
Cogent Security | $11,000,000 | (Jul 15, 2025)